Gulf International Bank UK Ltd boosted its stake in Becton Dickinson and Co (NYSE:BDX) by 3.8% in the third quarter, HoldingsChannel reports. The firm owned 89,172 shares of the medical instruments supplier’s stock after purchasing an additional 3,282 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Becton Dickinson and were worth $23,273,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Acropolis Investment Management LLC acquired a new position in Becton Dickinson and during the third quarter worth about $101,000. Truvestments Capital LLC acquired a new position in Becton Dickinson and during the third quarter worth about $105,000. Almanack Investment Partners LLC. acquired a new position in Becton Dickinson and during the second quarter worth about $105,000. Bartlett & Co. LLC raised its stake in Becton Dickinson and by 2,900.0% during the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after acquiring an additional 435 shares in the last quarter. Finally, Bridgeworth LLC acquired a new position in Becton Dickinson and during the second quarter worth about $131,000. 92.60% of the stock is owned by institutional investors and hedge funds.
NYSE BDX opened at $240.69 on Wednesday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. Becton Dickinson and Co has a twelve month low of $209.91 and a twelve month high of $265.87. The company has a market cap of $63.03 billion, a P/E ratio of 25.39, a PEG ratio of 1.40 and a beta of 1.19.
Several research analysts have commented on BDX shares. Morgan Stanley boosted their target price on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 4th. Wells Fargo & Co upped their target price on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Barclays assumed coverage on Becton Dickinson and in a report on Monday, October 15th. They issued an “equal weight” rating and a $278.00 target price on the stock. Royal Bank of Canada restated a “hold” rating and set a $248.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, KeyCorp reaffirmed a “buy” rating and set a $264.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $254.71.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Read More: Earnings Per Share (EPS) Explained
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.